Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

AtriCure Inc

Healthcare US ATRC

28.44USD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

27.6428.88
LowHigh

52 Week Range

27.2643.18
LowHigh

Fundamentals

  • Previous Close 28.44
  • Market Cap1385.87M
  • Volume727353
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA11.08M
  • Revenue TTM534.53M
  • Revenue Per Share TTM11.19
  • Gross Profit TTM 400.78M
  • Diluted EPS TTM-0.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.16300M -43.67400M -29.84700M -46.19800M 50.39M
Minority interest - - - - -
Net income -11.44800M -44.69800M -30.43800M -46.46600M 50.20M
Selling general administrative 311.02M 291.36M 253.14M 231.27M 19.85M
Selling and marketing expenses - - - - -
Gross profit 397.74M 347.52M 300.37M 245.94M 205.86M
Reconciled depreciation 20.53M 18.73M 14.81M 11.71M 10.44M
Ebit -4.28500M -37.26700M -22.92200M -54.37900M -47.29500M
Ebitda 16.25M -18.53400M -8.10900M -42.66900M -149.79500M
Depreciation and amortization 20.53M 18.73M 14.81M 11.71M -102.50000M
Non operating income net other - - - 1.46M 0.10M
Operating income -3.44700M -40.01300M -26.68300M -42.66900M -47.29500M
Other operating expenses 537.98M 505.32M 425.93M 373.05M 321.62M
Interest expense 5.88M 6.41M 6.92M 4.99M 4.92M
Tax provision 1.28M 1.02M 0.59M 0.27M 0.19M
Interest income 4.48M 4.43M 3.79M 1.99M 0.47M
Net interest income -1.39900M -1.97300M -3.13300M -2.99200M -4.45200M
Extraordinary items - - - - -
Non recurring - - - - 82.30M
Other items - - - - -
Income tax expense 1.28M 1.02M 0.59M 0.27M 0.19M
Total revenue 534.53M 465.31M 399.25M 330.38M 274.33M
Total operating expenses 401.19M 387.54M 327.05M 288.61M 253.16M
Cost of revenue 136.79M 117.78M 98.88M 84.44M 68.47M
Total other income expense net -6.71600M -3.66100M -3.16400M -3.52900M 97.68M
Discontinued operations - - - - -
Net income from continuing ops -11.44800M -44.69800M -30.43800M -46.46600M 50.20M
Net income applicable to common shares - - - -46.46600M 50.20M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 654.18M 609.33M 613.93M 585.45M 615.31M
Intangible assets 48.03M 56.47M 63.99M 39.34M 42.99M
Earning assets - - - - -
Other current assets 9.94M 9.43M 8.56M 5.48M 5.00M
Total liab 162.24M 148.36M 147.76M 128.69M 131.56M
Total stockholder equity 491.94M 460.97M 466.17M 456.75M 483.76M
Deferred long term liab - - - - -
Other current liab 3.12M 45.59M 44.68M 33.02M 36.09M
Common stock 0.05M 0.05M 0.05M 0.05M 0.05M
Capital stock 0.05M 0.05M 0.05M 0.05M 0.05M
Retained earnings -413.20300M -401.75500M -357.05700M -326.61900M -280.15300M
Other liab - - - 1.23M 1.22M
Good will 282.81M 234.78M 234.78M 234.78M 234.78M
Other assets - - 0.00000M 1.99M 0.95M
Cash 167.43M 122.72M 84.31M 58.10M 43.65M
Cash and equivalents - - - - -
Total current liabilities 81.52M 73.42M 74.57M 58.39M 56.45M
Current deferred revenue - - - - -
Net debt -79.41000M -46.19100M -9.81600M 10.98M 31.99M
Short term debt 3.12M 2.81M 2.53M 5.47M 1.76M
Short long term debt - 2.81M 2.53M - 1.76M
Short long term debt total 88.02M 76.53M 74.49M 69.08M 75.65M
Other stockholder equity 904.52M 863.71M 824.17M 787.42M 764.81M
Property plant equipment - - - 42.62M 36.17M
Total current assets 322.52M 267.83M 266.25M 215.21M 196.08M
Long term investments - - 0.00000M 51.51M 104.34M
Net tangible assets - - - 182.63M 205.98M
Short term investments - 0.00000M 52.98M 63.01M 75.44M
Net receivables 66.65M 60.34M 52.50M 42.69M 33.02M
Long term debt 61.87M 61.87M 60.59M 56.83M 59.74M
Inventory 78.49M 75.33M 67.90M 45.93M 38.96M
Accounts payable 78.40M 25.03M 27.35M 19.90M 18.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.57M -1.03500M -0.99300M -4.09600M -0.94800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.05M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -326.61900M -280.15300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.86M 2.87M 2.16M 1.99M 0.95M
Deferred long term asset charges - - - - -
Non current assets total 331.66M 341.50M 347.69M 370.23M 419.24M
Capital lease obligations 11.52M 11.86M 11.37M 12.24M 15.91M
Long term debt total - - - 56.83M 59.74M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M 30.23M 21.82M 60.89M 33.26M
Change to liabilities - - - -0.28900M 12.98M
Total cashflows from investing activities -14.55000M 30.23M - 44.01M 23.50M
Net borrowings -1.20100M -1.66900M - -0.89900M 3.83M
Total cash from financing activities 1.18M -3.60300M -0.03200M -7.05900M -7.64200M
Change to operating activities - - - -5.26300M 4.80M
Net income -11.44800M -44.69800M -30.43800M -46.46600M 50.20M
Change in cash 44.71M 38.41M 26.21M 14.45M 1.71M
Begin period cash flow 122.72M 84.31M 58.10M 43.65M 41.94M
End period cash flow 167.43M 122.72M 84.31M 58.10M 43.65M
Total cash from operating activities 57.33M 12.20M 4.48M -22.14100M -13.78000M
Issuance of capital stock - - - 0.00000M 0.00000M
Depreciation 20.53M 18.73M 14.81M 11.71M 10.44M
Other cashflows from investing activities -5.50000M 30.23M - - -
Dividends paid 0.00000M 0.00000M 0.06M 6.04M 12.36M
Change to inventory -2.25600M -7.74000M -21.83000M -7.30500M -4.27400M
Change to account receivables -5.61000M -8.30100M -9.87200M -8.98900M -10.08700M
Sale purchase of stock -11.16300M -6.95100M -6.55700M -12.20100M -18.01100M
Other cashflows from financing activities 1.18M 5.02M 7.52M 6.04M 11.19M
Change to netincome - - - 29.51M -72.81500M
Capital expenditures 9.05M 23.46M 42.00M 16.88M 9.75M
Change receivables - - - -8.98900M -10.08700M
Cash flows other operating - - - -2.29700M -3.46600M
Exchange rate changes - - - - -0.37200M
Cash and cash equivalents changes - - - 14.81M 1.71M
Change in working capital -4.28600M -18.35800M -18.24000M -18.88000M -4.84600M
Stock based compensation 44.69M 40.41M 35.73M 28.77M 28.08M
Other non cash items 7.85M 30.56M 2.62M 2.72M -182.43400M
Free cash flow 48.28M -11.25500M -37.51400M -39.02200M -23.53300M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATRC
AtriCure Inc		 - -% 28.44 - 384.62 2.59 2.96 2.55 83.94
ISRG
Intuitive Surgical Inc		 0.23 0.06% 403.18 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 - -% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.49 0.51% 95.87 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.21 2.28% 143.92 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure Inc

7555 Innovation Way, Mason, OH, United States, 45040

Key Executives

Name Title Year Born
Mr. Michael H. Carrel CEO, Pres & Director 1971
Ms. Angela L. Wirick CPA Chief Financial Officer 1978
Mr. Douglas J. Seith Chief Operating Officer 1966
Dr. Vinayak Doraiswamy Ph.D. Chief Scientific Officer 1972
Mr. Justin J. Noznesky Chief Marketing & Strategy Officer 1978
Mr. Salvatore Privitera J.D. Chief Technical Officer 1967
Mr. Karl S. Dahlquist C.C.E.P., CCEP, J.D. Chief Legal & Compliance Officer 1970
Valerie Storch-Willhaus VP of Corp. Marketing & Communications NA
Ms. Deborah Yount Chief HR Officer NA
Mr. Amalio Telenti M.D., Ph.D. Exec. VP & Chief Data Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.